PCA
FATE icon

Pallas Capital Advisors’s Fate Therapeutics FATE Stock Holding History

Pallas Capital Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.9K Buy
22,430
+7,756
+53% +$9.44K ﹤0.01% 846
2025
Q4 		$14.4K Sell
14,674
-2,085
-12% -$2.5K ﹤0.01% 882
2025
Q3 		$21.1K Buy
16,759
+1,423
+9% +$1.53K ﹤0.01% 866
2025
Q2 		$17.2K Buy
15,336
+1,104
+8% +$1.28K ﹤0.01% 847
2025
Q1 		$11.2K Buy
+14,232
New +$17.4K ﹤0.01% 760

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pallas Capital Advisors's FATE Position: Q1 2026 in Review

Pallas Capital Advisors increased its Fate Therapeutics (FATE) stake by 53% in Q1 2026, buying an estimated $9.44K and bringing the position to 22,430 shares worth $26.9K. The position accounts for ﹤0.01% of the portfolio, ranked #846.

Pallas Capital Advisors first reported a position in FATE in Q1 2025 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Pallas Capital Advisors held 22,430 shares of Fate Therapeutics worth $26.9K as of Q1 2026.
  • Pallas Capital Advisors bought 7,756 Fate Therapeutics shares in Q1 2026, an estimated $9.44K.
  • Fate Therapeutics made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q1 2026, its #846 holding.
  • Pallas Capital Advisors first reported a position in Fate Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.